Orally consumed cannabinoids: the effect of carrier oil on acute tissue distribution in male C57BL/6 mice DOI Creative Commons

Cody A.C. Lust,

Lyn M. Hillyer,

Mitchell Pallister

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Авг. 19, 2024

Abstract Background: Fundamental gaps in knowledge exist understanding the tissue distribution of cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), following oral ingestion. CBD THC are lipid-soluble bioavailability is increased when combined with long-chain fatty acid carrier oils prior to Oils eicosapentaenoic (EPA) docosahexaenoic (DHA) confer positive health benefits have yet be examined as a oil for cannabinoid delivery thus, examination warranted. Methods: This study investigated acute cannabinoids serum, adipose, brain, liver, heart, muscle male C57BL/6 mice at 1, 2, 3 hours (H) post Mice were gavaged (5 mg/kg) (1 either sesame (SES), mixed EPA/DHA (EPA/DHA), or DHA enriched carrier. With assistance Analytical Facility Bioactive Molecules (Toronto, Canada), concentration was quantified using liquid chromatography tandem mass spectrometry. Results: SES resulted significantly greater (p<0.05) across all tissues times compared n-3 PUFA oils. The ratio EPA:DHA modestly affected tissues, notably, brain. Heart had highest 1 2H post-oral gavage, adipose 3H which consistent three Conclusions: profiled greatest number to-date consumption lipid demonstrated non-uniform over time. proved far more effective delivering orally consumed two different containing Further developing our fundamental their from foods pharmaceuticals necessary establish specific pharmacokinetic profiles aid dosing strategies maximize bioactive potential cannabinoids.

Язык: Английский

Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting DOI Creative Commons

Tamer A. Addissouky,

Ibrahim El Tantawy El Sayed, Majeed M. A. Ali

и другие.

Bulletin of the National Research Centre/Bulletin of the National Research Center, Год журнала: 2024, Номер 48(1)

Опубликована: Янв. 22, 2024

Abstract Background Tobacco smoking remains a major preventable cause of disease and death worldwide. Combustible cigarettes release thousands chemicals that can initiate inflammatory pathways leading to smoking-related illness. This review aims synthesize current scientific knowledge on mechanisms smoking-induced disease, epidemiological trends, clinical strategies from recent literature. Main body the abstract At cellular level, cigarette smoke triggers oxidative stress through reactive oxygen species (ROS), causing DNA damage. provokes signaling cascades mediated by damage-associated molecular patterns (DAMPs), receptors like RAGE TLRs, downstream cytokines. Smoking also disrupts apoptosis autophagy. In lungs, inflammation play central roles in COPD pathogenesis. Smoking-induced damage, chronic inflammation, impaired immunity combine promote lung carcinogenesis. For cardiovascular endothelial dysfunction, platelet activation, atherogenesis oxidized LDL effects nitric oxide adhesion molecules. Short conclusion Given unequivocal evidence health risks, cessation is critical reducing disability. Both counseling pharmacotherapy have proven efficacy for quitting, but limited long-term. Emerging nicotine products e-cigarettes unknown impacts population health. Comprehensive efforts encompassing prevention, screening, treatment innovation, harm reduction, policy reform focused curbing smoking-attributable morbidity mortality are warranted.

Язык: Английский

Процитировано

34
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders DOI Creative Commons
Olivier J. Manzoni,

Antonia Manduca,

Viviana Trezza

и другие.

Trends in Pharmacological Sciences, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Cannabidiol (CBD), the primary non-intoxicating compound in cannabis, is currently approved for treating rare, treatment-resistant seizures. Recent preclinical research suggests that CBD's multifaceted mechanisms of action brain, which involve multiple molecular targets, underlie its neuroprotective, anti-inflammatory, anxiolytic, and antipsychotic effects. Clinical trials are also exploring therapeutic potential beyond current uses. This review focuses on polypharmacological profile discusses latest clinical findings regarding efficacy neuropsychiatric disorders. Existing evidence ability to modulate signaling pathways may benefit disorders, we propose further areas clarify mechanisms, address data gaps, refine indications.

Язык: Английский

Процитировано

3
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review DOI Creative Commons
Kuldeep Singh, Bharat Bhushan, Dilip Kumar Chanchal

и другие.

Behavioural Neurology, Год журнала: 2023, Номер 2023, С. 1 - 17

Опубликована: Окт. 12, 2023

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's which present major healthcare concerns on a worldwide scale. Despite lack available therapies, been shown to possess variety pharmacological effects preclinical clinical studies, making it an intriguing competitor. review brings together most recent findings endocannabinoid neurotransmitter systems, as well anti-inflammatory pathways, that underlie CBD's modes action. Synthesized efficacy safety assessments range illnesses are included, covering human trials, vitro animal models. The investigation includes how could protect neurons, control neuroinflammation, fend off oxidative stress, manage neuronal excitability. study emphasizes existing studies future possibilities research, addressing research issues such regulatory complications contradicting results, advocates further ideal dose methodologies. By emphasizing improve patient well-being, this presents revised viewpoint suitability intervention illnesses.

Язык: Английский

Процитировано

26
Drug carrier wonders: Synthetic strategies of zeolitic imidazolates frameworks (ZIFs) and their applications in drug delivery and anti-cancer activity DOI

Hamza Akhtar,

Umay Amara,

Khalid Mahmood

и другие.

Advances in Colloid and Interface Science, Год журнала: 2024, Номер 329, С. 103184 - 103184

Опубликована: Май 17, 2024

Язык: Английский

Процитировано

14
Novel rapid treatment options for adolescent depression DOI Creative Commons
Sandra Ledesma‐Corvi, Jordi Jornet-Plaza, Laura Gálvez‐Melero

и другие.

Pharmacological Research, Год журнала: 2024, Номер 201, С. 107085 - 107085

Опубликована: Фев. 2, 2024

There is an urgent need for novel fast-acting antidepressants adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of main research lines our group characterize at preclinical level approaches rapid-acting adolescence. The present review summarizes potential use in adolescence non-pharmacological options, such as neuromodulators (electroconvulsive therapy and other innovative types brain stimulation), well pharmacological including consciousness-altering drugs (mainly ketamine but also classical psychedelics) cannabinoids cannabidiol), with promising responses. Following a brief analytical explanation depression, we general introduction each therapeutical approach together clinical evidence supporting its beneficial extrapolated from prior successful examples adults), then report recent ongoing studies will aid improving inclusion these therapies clinic, by considering sex-, age-, dose-related differences, factors might affect efficacy long-term safety. Finally, conclude providing future avenues maximize treatment response, more importance designing testing options safe depression.

Язык: Английский

Процитировано

9
Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease DOI Creative Commons
Jordan P. Hickey, Andrila E. Collins,

Mackayla L. Nelson

и другие.

Current Issues in Molecular Biology, Год журнала: 2024, Номер 46(5), С. 4379 - 4402

Опубликована: Май 6, 2024

Alzheimer’s disease (AD) is a progressive neurodegenerative and the most common form of dementia globally. Although direct cause AD remains under debate, neuroinflammation oxidative stress are critical components in its pathogenesis progression. As result, compounds like cannabidiol (CBD) being increasingly investigated for their ability to provide antioxidant anti-inflammatory neuroprotection. CBD primary non-psychotropic phytocannabinoid derived from Cannabis sativa. It has been found beneficial outcomes variety medical conditions gaining increasing attention potential therapeutic application AD. not psychoactive lipophilic nature allows rapid distribution throughout body, including across blood–brain barrier (BBB). also possesses anti-inflammatory, antioxidant, neuroprotective properties, making it viable candidate treatment. This review outlines CBD’s mechanism action, role AD, effectiveness limitations preclinical models

Язык: Английский

Процитировано

9
Oral delivery of cannabidiol: Revealing the formulation and absorption challenges DOI
Andrejs Šitovs, Konstantīns Logviss, Līga Lauberte

и другие.

Journal of Drug Delivery Science and Technology, Год журнала: 2023, Номер 92, С. 105316 - 105316

Опубликована: Дек. 27, 2023

Язык: Английский

Процитировано

12
Spray freeze dried cannabidiol with dipalmitoylphosphatidylcholine (DPPC) for inhalation and solubility enhancement DOI Creative Commons
Waiting Tai, Jonathon C. Arnold, Hak‐Kim Chan

и другие.

International Journal of Pharmaceutics, Год журнала: 2024, Номер 659, С. 124235 - 124235

Опубликована: Май 17, 2024

Pulmonary delivery is an efficient route of administration to deliver cannabidiol (CBD) due the high bioavailability and fast onset action. The major formulation challenge poor aqueous solubility CBD. This study aimed produce inhalable CBD powders with enhanced characterise their solid-state properties. was spray freeze dried mannitol or trehalose dihydrate without dipalmitoylphosphatidylcholine (DPPC). All four had acceptable yields at > 70 % porous spherical particles. two crystalline contained less residual solvent than both amorphous ones. addition DPPC did not affect crystallinity level powders. Instead, made particles more porous, decreased particle size from 19-23 µm 11-13 µm, increased 0.36 µg/mL over 2 µg/mL. were dispersed a low resistance RS01 inhaler, showing aerosol performance emitted fractions 91-93 fine < 5 34-43 %. These formulations can be used as platform other cannabinoids by inhalation.

Язык: Английский

Процитировано

4
Cannabidiol and its application in the treatment of oral diseases: therapeutic potentials, routes of administration and prospects DOI Open Access

Zonghao Hu,

Zishun Qin,

Jinhong Xie

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 176, С. 116271 - 116271

Опубликована: Май 24, 2024

Cannabidiol (CBD), one of the most important active ingredients in cannabis, has been reported to have some pharmacological effects such as antibacterial and analgesic effects, therapeutic potential treatment oral diseases cancer, gingivitis periodontal diseases. However, there is a lack relevant systematic research reviews. Therefore, based on etiology clinical symptoms several common diseases, this paper focuses CBD pulp mucosal cancer temporomandibular joint The distribution function its receptors cavity are also summarized. In order provide reference for future further application CBD, we summarize possible routes administration corresponding characteristics. Finally, challenges faced while applying clinically solutions discussed, look future.

Язык: Английский

Процитировано

4
Hemp macromolecules: Crafting sustainable solutions for food and packaging innovation DOI
Rekha Chawla, Zhongxiang Fang

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 273, С. 132823 - 132823

Опубликована: Июнь 7, 2024

Язык: Английский

Процитировано

3